The new and improved 2nd Cell Therapy Analytical Development Summit Europe, now in Amsterdam, is returning as your go-to meeting to address key regulatory hurdles and developing standards for assay and analytical development in the European cell therapy market.

Maximise the speed of quality control, implement automation, improve characterisation of potency, safety and product with European cell therapy pioneers from the likes of Cellectis, Novo Nordisk, bluebird bio and Orgenesis.

Next generation cell therapies are emerging as game-changing treatments for cancer and beyond, but given their increasing complexities, developing robust, reliable, and in-depth analytical assays is critical to prove their safety and quality to the regulatory authorities. With a focus on critical analytical parameters and quality control, the 2nd Cell Therapy Analytical Development Summit Europe will offer valuable insights on optimising manufacturing processes and ensuring regulatory compliance. Spanning a variety of cell therapy modalities, analytical techniques, and strategic approaches, this is a must-attend meeting for anyone in the cell therapy analytical space - brought right to your doorstep!